LT3164380T - Lizinui specifiniai demetilazės-1 inhibitoriai - Google Patents

Lizinui specifiniai demetilazės-1 inhibitoriai

Info

Publication number
LT3164380T
LT3164380T LTEPPCT/US2015/038345T LT15038345T LT3164380T LT 3164380 T LT3164380 T LT 3164380T LT 15038345 T LT15038345 T LT 15038345T LT 3164380 T LT3164380 T LT 3164380T
Authority
LT
Lithuania
Prior art keywords
lysine
inhibitors
specific demethylase
demethylase
specific
Prior art date
Application number
LTEPPCT/US2015/038345T
Other languages
English (en)
Lithuanian (lt)
Inventor
Young K. Chen
Toufike Kanouni
Zhe Nie
Jeffrey Alan Stafford
James Marvin Veal
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of LT3164380T publication Critical patent/LT3164380T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEPPCT/US2015/038345T 2014-07-03 2015-06-29 Lizinui specifiniai demetilazės-1 inhibitoriai LT3164380T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020886P 2014-07-03 2014-07-03
PCT/US2015/038345 WO2016003917A1 (en) 2014-07-03 2015-06-29 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
LT3164380T true LT3164380T (lt) 2022-06-27

Family

ID=55019883

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEPPCT/US2015/038345T LT3164380T (lt) 2014-07-03 2015-06-29 Lizinui specifiniai demetilazės-1 inhibitoriai
LTEP19156976.3T LT3511319T (lt) 2014-07-03 2015-06-29 Lizinui specifinės demetilazės-1 inhibitoriai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP19156976.3T LT3511319T (lt) 2014-07-03 2015-06-29 Lizinui specifinės demetilazės-1 inhibitoriai

Country Status (29)

Country Link
US (3) US9902719B2 (enExample)
EP (2) EP3511319B1 (enExample)
JP (2) JP6663866B2 (enExample)
KR (1) KR102475498B1 (enExample)
CN (2) CN108530424B (enExample)
AU (1) AU2015284383B2 (enExample)
BR (1) BR112017000043A2 (enExample)
CA (1) CA2954049A1 (enExample)
CL (1) CL2016003422A1 (enExample)
CO (1) CO2017000549A2 (enExample)
CY (1) CY1125127T1 (enExample)
DK (2) DK3511319T3 (enExample)
EA (2) EA201891526A3 (enExample)
EC (1) ECSP17006821A (enExample)
ES (2) ES2907676T3 (enExample)
FI (1) FI3511319T3 (enExample)
HR (2) HRP20220414T1 (enExample)
HU (2) HUE058852T2 (enExample)
IL (2) IL249881B (enExample)
LT (2) LT3164380T (enExample)
MX (2) MX395534B (enExample)
PL (2) PL3511319T3 (enExample)
PT (2) PT3164380T (enExample)
RS (2) RS64423B1 (enExample)
SA (1) SA517380651B1 (enExample)
SG (2) SG10201802501RA (enExample)
SI (2) SI3511319T1 (enExample)
SM (2) SMT202200136T1 (enExample)
WO (1) WO2016003917A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015922A (es) 2015-06-12 2018-12-11 Oryzon Genomics Sa Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos.
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EP3429571B1 (en) 2016-03-15 2025-10-08 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
JP2019512546A (ja) 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Kdm1a標的会合を決定するための方法、およびそれに有用な化学プローブ
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3535420A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
BR112020000827A2 (pt) 2017-08-03 2020-07-21 Oryzon Genomics, S.A. métodos de tratamento de alterações de comportamento
PL3833670T3 (pl) * 2018-08-10 2024-08-19 Navire Pharma, Inc. Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka
JP7532386B2 (ja) 2019-02-01 2024-08-13 ハンミ ファーマシューティカルズ カンパニー リミテッド イミダゾピリジン誘導体化合物及びその用途
CN113365996B (zh) * 2019-02-01 2024-09-03 韩美药品株式会社 咪唑吡啶衍生化合物以及药物组成物
PH12021552251A1 (en) 2019-03-20 2022-07-25 Oryzon Genomics Sa Methods of treating borderline personality disorder
JP7535797B2 (ja) 2019-03-20 2024-08-19 オリソン ヘノミクス,ソシエダ アノニマ 化合物バフィデムスタット(vafidemstat)などkdm1a阻害剤を使用した注意欠陥多動性障害の処置方法
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
US11360505B2 (en) 2020-02-11 2022-06-14 Simmonds Precision Products, Inc. Distributed network time synchronization
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
TWI834127B (zh) * 2021-03-11 2024-03-01 大陸商南京明德新藥研發有限公司 噻吩類化合物及其應用
CN117062813A (zh) * 2021-03-24 2023-11-14 四川汇宇制药股份有限公司 一种多环化合物及其应用
BR112023020554A2 (pt) 2021-04-08 2023-12-05 Oryzon Genomics Sa Combinações de inibidores de lsd1 para o tratamento de cânceres mieloides
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いる悪性末梢神経鞘腫(mpnst)の治療法
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
EP4622635A1 (en) 2022-11-24 2025-10-01 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
WO2002026718A2 (en) * 2000-09-29 2002-04-04 Millennium Pharmaceutical, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
JP2005170792A (ja) * 2002-11-22 2005-06-30 Mitsubishi Pharma Corp L−プロリン誘導体およびその医薬としての用途。
CN1890228B (zh) 2003-12-11 2011-07-20 田边三菱制药株式会社 α-氨基酸衍生物及其作为药物的应用
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
WO2006129181A2 (en) * 2005-06-03 2006-12-07 Orchid Research Laboratories Limited Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
PT1924561E (pt) * 2005-09-01 2013-01-16 Lilly Co Eli Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados
JP2007197324A (ja) * 2006-01-23 2007-08-09 Toray Ind Inc 2,4,5−置換−1,3−アゾール誘導体
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
PE20081803A1 (es) 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
US20130096160A1 (en) 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
CA2866015A1 (en) * 2012-03-06 2013-09-12 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
DK3080100T3 (da) * 2013-12-11 2023-02-06 Celgene Quanticel Res Inc Hæmmere af lysinspecifik demethylase-1
US10011573B2 (en) * 2014-02-14 2018-07-03 The University Of British Columbia Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use
RS62874B1 (sr) * 2014-05-01 2022-02-28 Celgene Quanticel Research Inc Inhibitori lizin specifične demetilaze-1
FR3020945B1 (fr) 2014-05-16 2016-05-06 Oreal Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier
US10011583B2 (en) * 2014-06-27 2018-07-03 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
SG11201700007YA (en) * 2014-07-03 2017-01-27 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1

Also Published As

Publication number Publication date
MX2017000168A (es) 2017-05-01
CY1125127T1 (el) 2024-02-16
IL249881B (en) 2020-01-30
MX395534B (es) 2025-03-25
PL3164380T3 (pl) 2022-04-04
JP2017525668A (ja) 2017-09-07
ES2907676T3 (es) 2022-04-26
EP3164380A4 (en) 2018-07-18
HUE062558T2 (hu) 2023-11-28
JP6663866B2 (ja) 2020-03-13
US20190002456A1 (en) 2019-01-03
MX376207B (es) 2025-03-07
BR112017000043A2 (pt) 2018-07-17
ECSP17006821A (es) 2017-03-31
SI3164380T1 (sl) 2022-06-30
CA2954049A1 (en) 2016-01-07
MX2020010900A (es) 2022-09-13
SG11201610975RA (en) 2017-01-27
EP3164380B1 (en) 2022-02-09
EP3511319A1 (en) 2019-07-17
PT3511319T (pt) 2023-06-29
PL3511319T3 (pl) 2023-09-11
US20170129882A1 (en) 2017-05-11
EP3511319B1 (en) 2023-05-03
EP3164380A1 (en) 2017-05-10
JP6768857B2 (ja) 2020-10-14
CO2017000549A2 (es) 2017-04-20
RS64423B1 (sr) 2023-09-29
CN108530424A (zh) 2018-09-14
DK3511319T3 (da) 2023-07-31
LT3511319T (lt) 2023-08-25
JP2019108346A (ja) 2019-07-04
AU2015284383A1 (en) 2017-02-02
IL272130B (en) 2021-03-25
EA201790085A1 (ru) 2017-08-31
CN108530424B (zh) 2021-10-01
CN106795103A (zh) 2017-05-31
SI3511319T1 (sl) 2023-10-30
EA201891526A3 (ru) 2019-05-31
WO2016003917A1 (en) 2016-01-07
US20180127408A1 (en) 2018-05-10
CN106795103B (zh) 2019-07-12
SA517380651B1 (ar) 2020-09-30
DK3164380T3 (da) 2022-03-28
AU2015284383B2 (en) 2019-04-18
ES2948782T3 (es) 2023-09-19
EA033698B1 (ru) 2019-11-18
IL272130A (en) 2020-03-31
EA201891526A2 (ru) 2018-12-28
SG10201802501RA (en) 2018-05-30
KR20170018100A (ko) 2017-02-15
HRP20230595T1 (hr) 2023-09-15
RS63074B1 (sr) 2022-04-29
US10100046B2 (en) 2018-10-16
FI3511319T3 (fi) 2023-07-20
KR102475498B1 (ko) 2022-12-07
SMT202300205T1 (it) 2023-09-06
HUE058852T2 (hu) 2022-09-28
PT3164380T (pt) 2022-03-02
SMT202200136T1 (it) 2022-05-12
CL2016003422A1 (es) 2017-11-10
HRP20220414T1 (hr) 2022-05-27
US9902719B2 (en) 2018-02-27
IL249881A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
NO2023039I1 (no) Glofitamab
NL301167I2 (nl) Lumasiran
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3160956T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3511319T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3442972T3 (da) Bromdomænehæmmere
DK3171891T3 (da) Fremgangsmåde
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3006072T3 (da) Karadgang
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
LT3160952T (lt) Histono demetilazės inhibitoriai
EP3230438C0 (en) N-GLYCOSYLATION
NO2023016I1 (no) nirsevimab
DK3341379T3 (da) EZH2-hæmmere
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DE112015001664A5 (de) Betätigungsaktuator
DE112015005041A5 (de) Gargerätevorrichtung
DE102014000623A8 (de) Halbhohlnietelement
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DK3009858T3 (da) Skyradar
FI20145913A (fi) Staattorimekanismi
DE202014005655U8 (de) llluminationsvorrichtung